DIAGNOS Announces Date for Annual General and Special Meeting of Shareholders
DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a frontrunner in the early detection of critical health issues through its FLAIRE platform powered by Artificial Intelligence (AI), has revealed that the annual general and special meeting of shareholders (the “Meeting”) will be held on September 25, 2024, at 10 a.m.
Purpose of the Meeting
This meeting will fulfill several key objectives, including:
Annual Report and Financial Statements
Shareholders will receive the management's annual report along with the audited consolidated financial statements for the fiscal year ending March 31, 2024, as well as the independent auditor’s report pertaining to these documents.
Election of Directors
During the meeting, shareholders will have the chance to elect the Corporation's directors.
Auditor Reappointment
Moreover, there will be a proposal to reappoint Raymond Chabot Grant Thornton, LLP as the Corporation’s independent auditor for the coming year, along with a resolution empowering the directors to determine its remuneration.
Amendment to Stock Option Plan
A resolution to amend the Corporation’s existing stock option plan will also be put forward for approval. This amendment aims to increase the maximum number of common shares that can be issued under this plan by 2,000,000, as authorized by the Board of Directors.
Other Business
Lastly, the meeting will cover any other business that may properly arise during the Meeting or any adjournment thereof.
Attendance and Participation at the Meeting
Registered Shareholders and Non-registered Holders are encouraged to join via videoconferencing, especially if they do not plan to vote in person. For those wishing to vote, Registered Shareholders and duly appointed proxyholders can do so at the Corporation’s head office.
Voting by Proxy
The Corporation highly recommends that all shareholders cast their votes by proxy prior to the Meeting to ensure their opinions are represented.
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to the early detection of critical health issues through its FLAIRE Artificial Intelligence (AI) platform. This platform serves as the basis for developing advanced applications, particularly CARA (Computer Assisted Retina Analysis). CARA employs image enhancement algorithms to produce sharper, clearer, and more easily analyzable retinal images, providing a cost-effective solution for real-time screening of large patient populations.
Contact Information
For additional information, please contact:
Mr. Marc-André Massue, CFO and Secretary
DIAGNOS Inc.
Tel: 450-678-8882 ext. 235
Frequently Asked Questions
What is the date and time of DIAGNOS's annual meeting?
The annual general and special meeting is scheduled for September 25 at 10 a.m.
What are the main agenda items of the meeting?
The agenda includes receiving financial statements, electing directors, reappointing auditors, a stock option plan amendment, and addressing any other business.
How can shareholders participate in the meeting?
Shareholders can participate via videoconferencing or in person at the head office, with a recommendation to vote by proxy in advance.
What is the FLAIRE AI platform?
The FLAIRE platform is designed for the early detection of critical health issues, offering various applications like CARA for enhanced retinal image analysis.
Who can be contacted for more information?
Mr. Marc-André Massue, CFO and Secretary of DIAGNOS Inc., can be contacted at 450-678-8882 ext. 235 for more information.
